桉苗灰霉病初步研究

按苗灰霉病(Botrytis cinerea Pers.ex Fr.)是近年在云南省新发现的病害,过去未曾报道。该病多发生在按苗幼嫩的茎上部和叶片上,可造成按苗迅速死亡。早春连绵阴雨,气温较低,致使该病易造成流行,该病的流行也与管理措施密切相关。采取平衡施肥,加强苗期管理是最有效的预防措施。发病期可施用75％百菌清可湿性粉剂1:500倍;或70％敌克松可湿性粉剂与等量的50％多菌灵可湿性粉剂混用,稀释1000倍常量喷雾,每7～10天一次,连续喷2～3次,可有效地控制按苗灰霉病蔓延流行。     

新一代驱虫抗生素—莫西菌素

莫西菌素同伊维菌素一样 ,是一种目前广泛用于兽医临床的广谱、高效、新型大环内酯类驱虫抗生素 ,是美贝霉素家族中的一员。由于其独特的理化性质 ,在国外 ,已被广泛用于治疗奶牛、猪等动物体内外寄生虫病。文章对莫西菌素的理化特性、作用机制、药动学、制剂、药效、耐药性、毒性、残留等进行了较详细地综述 ,同时也介绍了减少耐药性产生的一些方法 ,为该药能在国内应用提供第一手资料 ,以求为兽医临床用药提供参考     

不同有机物对铁皮石斛试管苗生长发育的影响

研究不同有机物浸提液对铁皮石斛试管苗生长的影响。在相同的培养条件下，以8种含有不同有机物的培养基培养试管苗，60d后对试管苗的各种性状进行记录统计，并与对照（没加有机物提取液）进行比较分析。结果不同的有机物浸提液对试管苗的影响效果不一样。壮苗以加入白萝卜提取液、CH和CM为佳，生根以加入香蕉提取液为佳，要提高繁殖系数以不加有机物为佳。     

花粉多糖注射剂临床前抗肿瘤药效学预试

花粉多糖对小鼠Lewis肺癌(足趾接种)模型以200mg/kg,100mg/kg,50mg/kg三个剂量iv×10qd方案给药,实验显示高、中、低三个剂量组抑瘤率分别为48.01%,43.09%,31.38%。免疫实验以上述相同的给药方案,花粉多糖对荷Lweis肺癌小鼠NK细胞活性具有明显的提高和促进作用。     

银条茎尖培养快繁及离体根状茎的诱导

 以银条‘二细一粗’品种为试材, 研究了蔗糖浓度、激素组合对茎尖培养和快速繁殖的影响及温度、光照、蔗糖浓度等因素对根状茎离体诱导的影响。结果表明: 茎尖培养较理想的培养基为MS + 蔗糖4 % + 6-BA 0.5 mg·L ^{- 1} + NAA 0.1 mg·L ^{- 1} , 成苗率可达74.0 %。茎尖增殖较适培养基为MS + 6-BA 3.0 mg·L ^{- 1} + NAA 0.5 mg·L ^{- 1} , 每个外植体平均可产生5.6 个芽。根状茎诱导以MS + 蔗糖10 % + 6-BA 510 mg·L ^{- 1}+ CCC 500 mg·L ^{- 1}培养基, 20 ℃全黑暗培养效果最好。     

Amoxicillin—current use in swine medicine

Amoxicillin has become a major antimicrobial substance in pig medicine for the treatment and control of severe, systemic infections such as Streptococcus suis. The minimum inhibitory concentration 90% (MIC 90) is 0.06 μg amoxicillin/ml, and the proposed epidemiological cut‐off value (ECOFF) is 0.5 μg/ml, giving only 0.7% of isolates above the ECOFF or of reduced susceptibility. Clinical breakpoints have not been set for amoxicillin against porcine pathogens yet, hence the use of ECOFFs. It has also been successfully used for bacterial respiratory infections caused by Actinobacillus pleuropneumoniae and Pasteurella multocida. The ECOFF for amoxicillin against A. pleuropneumoniae is also 0.5 μg/ml demonstrating only a reduced susceptibility in 11.3% of isolates. Similarly, P. multocida had an ECOFF of 1.0 μg/ml and a reduced susceptibility in only 2.6% of isolates. This reduced susceptibility disappears when combined with the beta‐lactamase inhibitor, clavulanic acid, demonstrating that it is primarily associated with beta‐lactamase production. In contrast, amoxicillin is active against Escherichia coli and Salmonella species but using ECOFFs of 8.0 and 4.0 μg/ml, respectively, reduced susceptibility can be seen in 70.9% and 67.7% of isolates. These high levels of reduced susceptibility are primarily due to beta‐lactamase production also, and most of this resistance can be overcome by the combination of amoxicillin with clavulanic acid. Currently, amoxicillin alone is considered an extremely valuable antimicrobial in both human and animal medicine and remains in the critically important category of antibiotics alongside the fluoroquinolones and macrolides by the World Health Organization as well as the third‐ and fourth‐generation cephalosporins, but these cephalosporins show marked resistance to basic beta‐lactamase production and are only destroyed by the extended‐spectrum beta‐lactamases. Amoxicillin alone and in combination with clavulanic acid are currently classed together in Category 2 in the European Union. By reviewing the pharmacodynamic data and comparing this with pharmacokinetic data from healthy and infected animals and clinical trial data, it can be seen that the product has a good efficacy against S. suis and A. pleuropneumoniae, in spite of usage over many years. However, it may be much less efficacious on its own against E. coli, due to reduced susceptibility and resistance associated with beta‐lactamase production, which is largely overcome by the use of clavulanic acid. It is felt that this differentiation may be useful in future classification of amoxicillin alone, in comparison with its combined use with clavulanic acid and thereby preserve the use of the more critically important antibiotics in veterinary medicine and reducing the risk of their resistance being transmitted to human.     

美味牛肝菌中油脂提取工艺的研究

采用超声波辅助法提取美味牛肝菌中的油脂，在单因素（提取时间、液料比和温度）实验考察的基础上，以油脂提取率为指标，通过响应面法对美味牛肝菌油脂的提取工艺进行优化。实验结果表明：响应面回归模型显著，拟合性好，可用于预测油脂提取率；优化后的油脂提取工艺为：液料比34.2 mL/g，温度36℃，提取时间4.5 h，此条件下油脂提取率为3.54826 %，与模型预测值相符，表明优化的油脂提取工艺合理。     

新型莫西菌素浇泼剂对羊蜱蝇和消化道线虫驱虫药效评价

试验旨在通过新型莫西菌素（moxidectin,MOX）浇泼剂对羊的驱虫试验,评价MOX浇泼剂对羊蜱蝇和消化道线虫的临床药效。将150只阿勒泰羊经产母羊随机分为6组,每组25只,分别为不用药对照组、螨净药浴组、MOX注射组和MOX低（0.05 mL/（kg·BW））、中（0.1 mL/（kg·BW））和高（0.2 mL/（kg·BW））剂量浇泼组,试验期为1周。试验第1天按前述分组中方法和剂量驱虫1次。观察受试动物临床表现,测定给药前1天和给药后第7天体温、脉搏和呼吸（TPR）,血液生理、生化和尿常规指标;测定羊蜱蝇减虫率、治愈率。采取粪样测定消化道线虫每克粪中虫卵个数（EPG）减少率及转阴率。结果显示,与不用药对照组相比,给药后第7天各驱虫组TPR、血液生理、生化及尿常规指标均无显著差异（P>0.05）。螨净药浴组羊蜱蝇减虫率为43.7%,而MOX注射组及MOX低、中、高剂量浇泼组均为100%。螨净药浴组治愈率为13.0%,而MOX注射组及MOX低、中、高剂量浇泼组均为100%;与不用药对照组相比,螨净药浴组消化道线虫卵减少率为0,而MOX注射组及MOX低、中、高剂量浇泼组分别为91.6%、93.1%、94.9%和97.8%。螨净药浴组虫卵转阴率为0,而MOX注射组及MOX低、中、高剂量浇泼组分别为77.0%、69.2%、69.2%和84.6%。本试验结果表明,新型MOX浇泼剂对体外寄生虫和消化道线虫均有显著疗效,且优于螨净药浴,与MOX注射剂等效。实践应用中最适MOX浇泼剂量推荐为0.05 mL/（kg·BW）（即0.25 mg/（kg·BW））。     

迷迭香的药效及在兽医临床的应用

迷迭香为唇形科植物,喜温,原产地中海沿岸,广泛用于医药、油炸食品及各类油脂的保鲜。研究表明,迷迭香具有抗炎、抗氧化、抗菌、抗癌、护肝等药效作用,在兽医临床可能有广泛的应用前景。通过查阅国内外有关文献资料,综述了迷迭香药效和兽医临床应用的进展,为迷迭香的进一步研究提供参考。     

The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: induction of ovulation, hormone profiles, and inter-ovulatory intervals

The objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3–20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12 h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12 h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17β (E₂), and progesterone (P₄) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0 mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.